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As the second leading cause of cancer deaths, colorectal cancer is
a significant source of morbidity and mortality in Western devel-
oped countries. Recent epidemiological studies have demonstrated
a significant correlation between regular aspirin use and reduced
colon cancer incidence and mortality (Giovannucci et al, 1995;
Thun, 1996). Moreover, in patients with previous colon adenomas,
aspirin use has been correlated with a reduced risk of adenoma
recurrence (Greenberg et al, 1993). Aspirin has also been shown to
suppress both the incidence and size of both carcinogen-induced
rodent colon tumours (Craven and DeRubertis, 1992; Reddy et al,
1993) and spontaneous intestinal tumours in mice genetically
predisposed to intestinal tumour formation (Barnes and Lee,
1998). However, the optimal dosage, timing and duration of
aspirin chemoprevention have not been determined in animal
models of colon carcinogenesis or in prospectively controlled
human trials. The present study was designed to establish an
optimal time period and duration of aspirin treatment in the
chemoprevention of carcinogen-induced colon cancer in rats.
MATERIALS AND METHODS
Animals
Male Sprague-Dawley rats (n = 208) were purchased at 2 months
of age from Harlan Sprague-Dawley (Indianapolis, IN, USA)
2 weeks before the experiment. Rats had free access to food and
water throughout these studies and were housed in wire-bottom
cages to prevent coprophagy. All experimental procedures
described below were approved by the Institutional Animal Care
Program of the University of Texas Health Science Center (San
Antonio, TX, USA).
Reagents
Dietary components for the AIN-76A diet were purchased from
ICN (Costa Mesa, CA, USA). 1,2-Dimethylhydrazine (DMH),
acetylsalicylic acid (aspirin) and serum salicylate assay kit were
purchased from Sigma (St. Louis, MO, USA). All other chemicals
were of the highest grade available and were obtained commercially.
DMH vehicle contained 0.9% sodium chloride and 0.18% EDTA at
pH 6.5. DMH and vehicle were prepared 1 h before injection.
Experimental protocol
Upon receipt, rats were fed a modified AIN-76A diet (Reddy et al,
1993) made weekly in our laboratory as previously described
(Barnes and Lee, 1998). After 2 weeks of acclimation and moni-
toring, rats were randomly divided into one of eight treatment
groups as outlined below (n = 8 in groups 1 and 2, n = 32 in groups
3–8). During the various aspirin treatment periods specified below,
groups 2 and 4–8 were switched from the standard modified
AIN-76A diet to the same diet supplemented with 500 p.p.m.
aspirin. Based on a previous report (Reddy et al, 1993), this aspirin
dose should be sufficient to inhibit carcinogen-induced colon
tumours without significantly affecting gains in body weight. Rats
were weighed weekly throughout the study as a gross measure of
toxicity. Moreover, rats were given a single s.c. injection of DMH
(12 mg base kg–1 b.w., groups 3–8) or DMH vehicle alone (4 ml
kg–1 b.w., groups 1 and 2) once a week for 8 weeks according to an
established protocol for inducing rat colon cancer (Cameron et al,
1990). The treatment schedule was as follows:
Group DMH Aspirin Comments
1 None None Controls receiving DMH vehicle and no aspirin diet only
2 None Entire 30 weeks Controls for aspirin treatment and side-effects
3 Yes None Positive controls for tumour development
4 Yes 1st 8 weeks only Aspirin during colon cancer initiation period only
5 Yes Weeks 9–16 only Aspirin during promotional period only
6 Yes Weeks 1–16 only Aspirin during both initiation and promotional periods
7 Yes Weeks 9–30 only Aspirin during promotion and tumour development stages
8 Yes Entire 30 weeks Aspirin during the entire 30 week study
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After the 8-week initiation period, rats received no further injec-
tions and were killed 22 weeks later. Blood was collected by
cardiac puncture for measurement of serum salicylate level (as an
indicator of aspirin ingestion) using a commercial kit as previously
described (Lee et al, 1994). Each colon was then immediately
resected, rinsed with ice-cold phosphate-buffered saline (PBS,
pH 7.4), and examined macroscopically to document tumour
incidence, size and multiplicity by an observer blinded to treat-
ment. Macroscopically visible tumours were excised and fixed in
10% buffered formalin. Histopathological examination was
performed on haematoxylin and eosin stained, 4-mm-thick slide-
mounted tumour sections according to the criteria of Sunter et al
(1978).
Statistical analysis
All statistical analyses were performed using PRISM (GraphPad
Software, San Diego, CA, USA) statistical software. Data are
expressed as absolute numbers or as means ± s.e.m. Differences in
mean body weight per group, tumour multiplicity (defined as the
number of tumours per tumour-bearing rat), tumour volume
(mm3), and serum salicylate concentration were determined
using analysis of variance followed by Student–Newman–Keuls
multiple range tests. Differences in tumour incidence (defined as
the number of rats per group with tumours) were determined using
Fisher’s exact test. Statistical significance was accepted when
P<0.05.
RESULTS
To determine whether DMH treatment and/or 500 p.p.m. aspirin in
the diet had any significant effect on weight gain, rats were
weighed once a week throughout the experimental period. As
shown in Figure 1, there were no significant differences in weight
gain between various treatment groups. Also, blood was collected
at the time of sacrifice in order to verify aspirin ingestion. Only
rats consuming the aspirin diet at the end of the experimental
period (i.e. groups 2, 7 and 8) had significant blood salicylate
levels (Table 1), with no significant differences in the blood salicy-
late levels among these groups.
The effect of aspirin treatment during various stages of DMH-
induced carcinogenesis on tumour incidence is summarized in
Table 2. No tumours were noted in the DMH vehicle control rats
(groups 1 and 2). The majority of DMH-induced tumours were
found in the colon. Outside the colon, most tumours were located
in the duodenum; however, one rat each in groups 3 and 4 had a
zymbal gland tumour, and one rat each in groups 3 and 6 and two
rats in group 5 had peritoneal metastases. Aspirin treatment
throughout the carcinogenic period (i.e. group 8) was the only
regimen which significantly reduced colon tumour incidence when
compared with the DMH/no aspirin control group (i.e. group 3).
Furthermore, group 8 was also the only experimental group which
demonstrated a significant decrease in mean tumour volume when
compared with the DMH/no aspirin control group 3 (Table 3). In
contrast, intervention with aspirin during weeks 1–8 (i.e. group 4)
or weeks 9–16 (i.e. group 5) caused a significant increase in mean
colon tumour volume or total tumour volume when compared with
the DMH/no aspirin control group (i.e. group 3). Finally, none of
the treatment regimens used here significantly affected tumour
multiplicity (group means, ranging from 1.5 ± 0.3 to 1.9 ± 0.2
tumours per tumour-bearing rat).
DISCUSSION
The purpose of the present study was to determine an optimal time
period and duration of aspirin treatment for the chemoprevention
of colon cancer development in a rat model of carcinogen-induced
colon cancer. Results indicate that only aspirin administration
throughout the entire carcinogenic period significantly reduced















































Figure 1 Mean (s.e.m.) rat body weight in grams for each treatment group
as defined in the Materials and Methods section. There were no significant
differences in body weight gain between the various treatment groups
Table 1 Effect of aspirin intervention during different stages of DMH-induced carcinogenesis on blood salicylate levels in rats
Treatment groupa
12 34567 8
Aspirin duration (weeks) N/Ab 1–30 N/A 1–8 9–16 1–16 9–30 1–30
Blood salicylate 0 ± 0c 4.8 ± 0.2d 0 ± 0c 0 ± 0c 0 ± 0c 0 ± 0c 6.0 ± 0.3d 4.8 ± 0.2d
aRats received a subcutaneous injection of DMH vehicle (groups 1 and 2) or DMH (groups 3–8) once a week for 8 weeks, then no further
injections for an additional 22 weeks; they were fed either a modified AIN-76A diet or the same diet supplemented with 500 p.p.m. aspirin as
described in the Materials and methods section. Data are the means ± s.e.m. serum salicylate levels (mg dl–1) in blood collected at the time of
death using a commercial kit as previously described (Lee et al, 1994). bRats consumed the no aspirin diet throughout the experimental period.
c0 = Undetectable. dSignificantly different from no aspirin control groups, P<0.05; no significant differences between groups with the same
superscript.1648 CJ Barnes and M Lee
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research has demonstrated that continuous aspirin use suppressed
spontaneous intestinal adenoma formation in a mouse model of
familial adenomatous polyposis (Barnes and Lee, 1998). Also,
aspirin inhibited carcinogen-induced rat colon tumours in a rat
model when the drug was administered either throughout the
carcinogenic process (Reddy et al, 1993) or given starting 1 week
before and ending 1 week after carcinogen exposure (Craven and
DeRubertis, 1992). Aspirin did not inhibit carcinogen-induced rat
colon cancer when given just during the initiation period of
carcinogenesis (Barnes et al, 1998a), when aspirin use started
1 week after carcinogen exposure (Craven and DeRubertis, 1992),
or when aspirin was administered concomitantly with cholic acid
during the promotion or the progression stages of a rodent colon
cancer model (Pence et al, 1995). Moreover, previous research
results using aberrant crypt foci (ACF) as a surrogate end point
biomarker indicate that ACF formation was initially suppressed
when aspirin was administered during the initiation period of
carcinogenesis, but the initial aspirin-induced suppression is
reversible upon cessation of aspirin treatment (Barnes et al, 1997).
With one exception (Craven and DeRubertis, 1992), the present
data are in agreement with previous research on aspirin chemopre-
vention of carcinogen-induced colon cancer in rodents.
Importantly, the present report is the first demonstration using a
single protocol of the necessity of extended aspirin administration
for chemoprevention of colon cancer.
Although the precise mechanisms by which aspirin and other
non-steroidal anti-inflammatory drugs (NSAIDs) exert their
chemopreventive effects remain unclear, several lines of evidence
suggest that this class of drugs inhibits gastrointestinal tumours
via acetylation of cyclo-oxygenase (COX) isozymes and subse-
quent inhibition of intestinal prostaglandin production (Meade et
al, 1993; Williams et al, 1997). First, the inducible isozyme COX-
2 is elevated in human adenomas and adenocarcinomas (Eberhart
et al, 1994; Kargman et al, 1995), in carcinogen-induced rodent
tumours (DuBois et al, 1996), and in spontaneously occurring
intestinal adenomas in two separate mouse models of familial
adenomatous polyposis (FAP) (Oshima et al, 1996; Williams et al,
1996). Second, Oshima et al (1996) recently demonstrated that
crossbreeding COX-2 gene knockout mice with ApcD716 knockout
mice (which normally develop hundreds of spontaneous intestinal
polyps) dramatically reduced the number and size of intestinal
polyps. Finally, various structurally unrelated NSAIDs, including
aspirin, sulindac and the novel selective COX-2 inhibitors MF-
tricyclic and SC-58635, have been shown to inhibit tumour forma-
tion in carcinogen-treated rodents (Craven and DeRubertis, 1992;
Reddy et al, 1993, 1996; Rao et al, 1995) and in mouse models of
FAP (Boolbol et al, 1996; Jacoby et al, 1996; Oshima et al, 1996;
Chiu et al, 1997; Barnes and Lee, 1998).
Alternatively, aspirin and other NSAIDs may inhibit tumour
formation via a prostaglandin independent pathway through
Table 2 Effect of aspirin intervention during different stages of DMH-induced carcinogenesis on tumour incidence in rats
Treatment groupa 3 4 5 678
Aspirin duration (weeks) N/Ab 1–8 9–16 1–16 9–30 1–30
Tumour incidence (%)
Colon 15 (47) 10 (31) 12 (38) 14 (44) 15 (47) 5 (16)d
Small intestine/otherc 6 (19) 7 (22) 9 (28) 5 (16) 4 (13) 6 (19)
Total 19 (59) 13 (41) 17 (53) 17 (53) 15 (47) 10 (31)e
aRats received a subcutaneous injection of DMH once a week for 8 weeks, then no further injections for an additional 22 weeks, and were fed
either a modified AIN-76A diet or the same diet supplemented with 500 p.p.m. aspirin as described in the Materials and methods section.
Tumour incidence was defined as the number of rats per group with tumours in each category (also as %), n = 32 per group. No tumours
were noted in the control rats (groups 1 and 2). bRats consumed the no aspirin diet throughout the experimental period. cTumours outside the
colon were found primarily in the duodenum, but tumours in the jejunum, zymbal gland tumours and peritoneal metastatic tumours also
occurred. dSignificantly different from groups 3, 6 and 7 in colon tumour incidence, P < 0.05. eSignificantly different from group 3 in total
tumour incidence, P < 0.05.
Table 3 Effect of aspirin intervention during different stages of DMH-induced carcinogenesis on tumour volume in rats
Treatment groupa 34567 8
Aspirin duration (weeks) N/Ab 1–8 9–16 1–16 9–30 1–30
Tumour volume
Colon 103.6 ± 17.3 132.2 ± 49.1 183.3 ± 20.2d 97.4 ± 11.7 69.2 ± 15.5 22.7 ± 12.8e
SI/otherc 169.6 ± 24.7 530.8 ± 61.8f 221.7 ± 45.7 250.3 ± 92.3 344.0 ± 116.6 74.1 ± 21.2
Total 124.7 ± 14.5 311.6 ± 48.1d 192.4 ± 20.4g 88.2 ± 9.8 130.2 ± 29.9 52.7 ± 12.4h
aRats received a subcutaneous injection of DMH once a week for 8 weeks, then no further injections for an additional 22 weeks; they were fed either a modified
AIN-76A diet or the same diet supplemented with 500 p.p.m. aspirin as described in the Materials and methods section. Data are the means (s.e.m.) tumour
volume (mm3) in each group (n = 32 per group) and in each category. bRats consumed the no aspirin diet throughout the experimental period. cTumours outside
the colon were found primarily in the duodenum, but tumours in the jejunum, zymbal gland tumours and peritoneal metastatic tumours also occurred. SI, small
intestine. dSignificantly different (i.e. higher) from all other groups in same tumour category, P<0.05. eSignificantly different (i.e. lower) from groups 3–6 in colon
tumour volume, P<0.05. fSignificantly different (i.e. higher) from groups 3, 5, 6 and 8 in SI/other tumour volume, P<0.05. gSignificantly different (i.e. higher) from
groups 6 and 8 in total tumour volume, P<0.05. hSignificantly different (i.e. lower) from groups 3–5 in total tumour volume, P<0.05.Aspirin and colon tumours 1649
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restoration of normal intestinal mucosal homeostasis, possibly by
reducing cell proliferation (Barnes et al, 1995) and/or inducing
apoptosis (Barnes et al, 1998b; Piazza et al, 1995; Morin et al,
1996). Additional mechanisms by which aspirin might also
suppress colon tumour formation include acetylation of other
protein(s) and/or other biological molecules (Abramson et al,
1985; Marnett, 1992), or via the production of 15-HETE from
COX-2 after aspirin acetylation (Lecomte et al, 1994).
In the present study, aspirin was given at a moderate therapeutic
dose (i.e. equivalent to a human antiarthritic dose of between four
and eight 325-mg tablets per day); under this protocol, aspirin
could work directly on DMH activation, on post-DMH activation
events, or in both capacities depending on the specific treatment
regimen. We have previously reported that aspirin given during the
initiation period suppresses the formation of single aberrant
crypts, but not the rate of ACF growth to multicrypt foci once
formed (Barnes et al, 1997). Available data from our past research
(Barnes et al, 1997, 1998a) and this report suggest that aspirin
administration during the DMH induction process does not
prevent molecular or cellular carcinogenic changes, but rather
decreases the expression of this initiated phenotype. With intermit-
tent aspirin intervention, the numbers and size of carcinogen-
induced tumours are either similar to or actually surpass those
parameters in the DMH/no aspirin treatment group. The
phenomena of reversibility of a suppressive action has also been
observed with sulindac, another NSAID, in patients with familial
adenomatous polyposis (Giardiello, 1994). Likewise, a recent
epidemiological study on aspirin use and colon cancer incidence
and mortality stressed the need for many years of regular aspirin
use in order to reap any chemopreventive benefit (Giovannucci et
al, 1995). Taken together, available data suggest that continuous
aspirin use for an extended period is needed to gain any chemo-
preventive benefits. The potential reversibility of NSAID chemo-
prevention and the need for extended aspirin use to reap a
chemopreventive benefit must be considered when recommending
aspirin use for colorectal cancer chemoprevention in humans.
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